Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against streptococcus pneumoniae polysaccharides: Response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine

Clinical and Vaccine Immunology

Volumn 17, Issue 4, 2010, Pages 674-682

  Elberse, Karin E M ^a   Tcherniaeva, Irina ^a   Berbers, Guy A M ^a   Schouls, Leo M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOMETRY; IMMUNIZATION; IMMUNOASSAY; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SERUM; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; CROSS REACTIONS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOASSAY; IMMUNOGLOBULIN G; INFANT; MICROSPHERES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; VACCINATION; YOUNG ADULT;

EID: 77950643075     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00408-09     Document Type: Article

References (30)

1. Berbers, G. A., and N. Jones. 2008. Serological surveillance of the effect of the changes to pertussis vaccines in the NIP from 2004 till 2008. Switch from whole cell to acellular vaccine in children of 1 year of age (ISRCTN97785537). RIVM report. National Institute for Public Health and the Environment, Bilthoven, Netherlands.
2. Biagini, R. E., S. A. Schlottmann, D. L. Sammons, J. P. Smith, J. C. Snawder, C. A. Striley, B. A. MacKenzie, and D. N. Weissman. 2003. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin. Diagn. Lab. Immunol. 10:744-750.
3. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, and K. Edwards. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19:187-195.
4. Capeding, M. Z., T. Puumalainen, C. P. Gepanayao, H. Kayhty, M. G. Lucero, and H. Nohynek. 2003. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein-conjugated pneumo-coccal vaccine in Filipino infants. BMC Infect. Dis. 3:17.
5. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22F polysac-charide absorption improves the specificity of a pneumococcal- polysaccha-ride enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
6. Dagan, R. 2002. Immunisation with a pneumococcal 7-valent conjugate vaccine. Int. J. Clin. Pract. 56:287-291.
7. de Voer, R. M., R. M. Schepp, F. G. Versteegh, F. R. van der Klis, and G. A. Berbers. 2009. Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin. Vaccine Immunol. 16:433-436.
8. Ekstrom, N., M. Vakevainen, J. Verho, T. Kilpi, and H. Kayhty. 2007. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect. Immun. 75:1794-1800.
9. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski, E. Herva, A. Takala, H. Kayhty, P. Karma, R. Kohberger, G. Siber, and P. H. Makela. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
10. Feavers, I., I. Knezevic, M. Powell, E. Griffiths, and WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. 2009. Challenges in the evaluation and licensing of new pneumo-coccal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27:3681-3688.
11. Findlow, H., G. Laher, P. Balmer, C. Broughton, E. D. Carrol, and R. Borrow. 2008. Competitive inhibition flow analysis assay for the non-culture detection of pneumococcal serotype capsular polysaccharide. Clin. Vaccine Immunol. 16:222-229.
12. Goldblatt, D., J. Southern, L. Ashton, P. Richmond, P. Burbidge, J. Tasevska, A. Crowley-Luke, N. Andrews, R. Morris, R. Borrow, K. Cartwright, and E. Miller. 2006. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25:312-319.
13. Gottschalk, P. G., and J. R. Dunn. 2005. The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal. Bio-chem. 343:54-65.
14. Jansen, A. G., G. D. Rodenburg, S. C. de Greeff, E. Hak, R. H. Veenhoven, L. Spanjaard, L. M. Schouls, E. A. Sanders, and A. van der Ende. 2009. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 27:2394-2401.
15. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, and N. Pierce. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
16. Lal, G., P. Balmer, E. Stanford, S. Martin, R. Warrington, and R. Borrow. 2005. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J. Immunol. Methods 296:135-147.
17. Lee, H., M. H. Nahm, R. Burton, and K. H. Kim. 2009. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin. Vaccine Immunol. 16:376-381.
18. Nielsen, S. V., U. B. Sorensen, and J. Henrichsen. 1993. Antibodies against pneumococcal C-polysaccharide are not protective. Microb. Pathog. 14:299-305.
19. O'Brien, K. L., L. H. Moulton, R. Reid, R. Weatherholtz, J. Oski, L. Brown, G. Kumar, A. Parkinson, D. Hu, J. Hackell, I. Chang, R. Kohberger, G. Siber, and M. Santosham. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362:355-361.
20. Pickering, J. W., T. B. Martins, R. W. Greer, M. C. Schroder, M. E. Astill, C. M. Litwin, S. W. Hildreth, and H. R. Hill. 2002. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysac-charides. Am. J. Clin. Pathol. 117:589-596.
21. Plikaytis, B. D., D. Goldblatt, C. E. Frasch, C. Blondeau, M. J. Bybel, G. S. Giebink, I. Jonsdottir, H. Kayhty, H. B. Konradsen, D. V. Madore, M. H. Nahm, C. A. Schulman, P. F. Holder, T. Lezhava, C. M. Elie, and G. M. Carlone. 2000. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J. Clin. Microbiol. 38:2043-2050.
22. Prentice, R. L. 1976. A generalization of the probit and logit methods for dose response curves. Biometrics 32:761-768.
23. Quataert, S., D. Martin, P. Anderson, G. S. Giebink, J. Henrichsen, M. Leinonen, D. M. Granoff, H. Russell, G. Siber, H. Faden, D. Barnes, and D. V. Madore. 2001. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol. Invest. 30:191-207.
24. Quataert, S. A., C. S. Kirch, L. J. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
25. Quataert, S. A., K. Rittenhouse-Olson, C. S. Kirch, B. Hu, S. Secor, N. Strong, and D. V. Madore. 2004. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S (f). Clin. Diagn. Lab. Immunol. 11:1064-1069.
26. Romero-Steiner, S., J. Fernandez, C. Biltoft, M. E. Wohl, J. Sanchez, J. Feris, S. Balter, O. S. Levine, and G. M. Carlone. 2001. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin. Vaccine Immunol. 8:1115-1119.
27. Skovsted, I. C., M. B. Kerrn, J. Sonne-Hansen, L. E. Sauer, A. K. Nielsen, H. B. Konradsen, B. O. Petersen, N. T. Nyberg, and J. O. Duus. 2007. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumo-coccal enzyme-linked immunosorbent assays. Vaccine 25:6490-6500.
28. Sorensen, U. B., and J. Henrichsen. 1984. C-polysaccharide in a pneumo-coccal vaccine. Acta Pathol. Microbiol. Immunol. Scand. C 92:351-356.
29. World Health Organization. 2005. Recommendations for the production and control of pneumococcal conjugate vaccines. World Health Organ. Tech. Rep. Ser. 927:64-98.
30. Yu, X., Y. Sun, C. Frasch, N. Concepcion, and M. H. Nahm. 1999. Pneumo-coccal capsular polysaccharide preparations may contain non-C-polysaccha-ride contaminants that are immunogenic. Clin. Diagn. Lab. Immunol. 6:519-524.